36. Fergusson D., Doucette S., Glass K. C., et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ. 2005; 330: 396.
37. Menzies K. B. 2006 PDAC Regarding the Results of FDA’s Ongoing Meta-analysis of Suicidality Data from Adult Antidepressant Trials. FDA. 2006 Dec 1.
38. Schelin E. M. [Healthy skepticism is the best medicine]. Ugeskr Læger. 2010; 172: 3361.
39. Lexchin J., Light D. W. Commercial influence and the content of medical journals. BMJ. 2006; 332: 1444–7.
40. Gorman J. M., Korotzer A., Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr. 2002; 7(4 Suppl. 1): 40–4.
41. Escitalopram (Lexapro) for depression. Medical Letter. 2002; 44: 83–4.
42. Melander H., Ahlqvist-Rastad J., Meijer G., et al. Evidence b(i)ased medicine – selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 2003; 326: 1171–3.
43. Carlsen L. T. [A diffi cult balance]. Tænk + Test. 2003; 32: 30–3.
44. Lindberg M. [Interesting regard for exports]. Dagens Medicin. 2002 Nov 29.
45. [The Danish Drug Agency gives Lundbeck hindwind]. Politiken. 2004 Sept 13.
46. [Treatment with antidepressants]. Danish Institute for Rational Drug Therapy. 2004 Sept 10.
47. Dyer O. Lundbeck broke advertising rules. BMJ. 2003; 326: 1004.
48. Cipriani A., Santilli C., Furukawa T. A., et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2009; 2: CD006532.
49. Turner E. H., Matthews A. M., Linardatos E., et al. Selective publication of antidepressant trials and its infl uence on apparent efficacy. N Engl J Med. 2008; 358: 252–60.
50. Gartlehner G., Hansen R. A., Morgan L. C., et al. Comparative benefi ts and harms of secondgeneration antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med. 2011; 155: 772–85.
51. Dyer O. Lundbeck broke advertising rules. BMJ. 2003; 326: 1004.
52. Masculine. Available online at: www.sprunk-jansen.com/da (accessed 2012 October 28).
53. Svansø V. L. [Lundbeck needs to fi ght for the company’s image]. Berlingske. 2011 May 14.
54. Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.
55. US Department of Justice. Drug Maker Forest Pleads Guilty; to pay more than $313 million to resolve criminal charges and False Claims Act allegations. 2010 Sept 15.
56. Hyltoft V. [Lundbeck partner in settlement about suicides]. Berlingske. 2011 Feb 8.
57. Meier B., Carey B. Drug maker is accused of fraud. New York Times. 2009 Feb 25.
58. Edwards J. Suit vs. Forest Labs names execs linked to alleged lies about Lexapro, Celexa. CBS News, Moneywatch. 2009 Feb 26.
59. Meier B. A medical journal quandary: how to report on drug trials. New York Times. 2004 June 21.
60. Harris G. Document details plan to promote costly drug. New York Times. 2009 Sept 1.
61. US Senate, Committee on Finance. Letter about Lexapro documents. 2009 Aug 12. Available online at: www.nytimes.com/packages/pdf/politics/20090831MEDICARE/20090831_MEDICARE. pdf (accessed 2011).
62. Olfson M., Blanco C., Liu S. M., et al. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry. 2012; Aug 6: 1–10.
63. Tyrer P., Kendall T. The spurious advance of antipsychotic drug therapy. Lancet. 2009; 373: 4–5.
64. Rosenheck R. A. Pharmacotherapy of fi rst-episode schizophrenia. Lancet. 2008; 371: 1048–9.
65. Kahn R. S., Fleischhacker W. W., Boter H., et al. Effectiveness of antipsychotic drugs in fi rst-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008; 371: 1085–97.
66. Stark J. McGorry aborts teen drug trial. Sydney Morning Herald. 2011 Aug 21.
67. Leucht S., Corves C., Arbter D., et al. Second-generation versus fi rst-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009; 373: 31–41.
68. 68 Safer D. J. Design and reporting modifi cations in industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis. 2002; 190: 583–92.
69. Thornley B., Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ. 1998; 317: 1181–4.
70. Pfizer memorandum. 1989 April 26.
71. Duggan L., Fenton M., Rathbone J., et al. Olanzapine for schizophrenia. Cochrane Database Syst Rev. 2005; 2: CD001359.
72. Lenzer J. Drug company tries to suppress internal memos. BMJ. 2007; 334: 59.
73. Geddes J., Freemantle N., Harrison P., et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000; 321: 1371–6.
74. Larsen N.-E. [New medicine has considerable adverse effects]. Dagens Medicin. 2001 Sept 27.
75. Sheller S. A. The Largest Pharma Fraud Whistleblower Case in US history totaling $1.4 billion. Press release. 2009 Jan 15. Available online at: www.reuters.com/article/2009/01/15/idUS182128+15-Jan-2009+PRN20090115 (accessed 17 July 2013).
76. Berenson A. Eli Lilly said to play down risk of top pill. New York Times. 2006 Dec 17.
77. Spielmans G. I., Parry P. I. From evidence-based medicine to marketing-based medicine: evidence from internal industry documents. Bioethical Inquiry. 2010. DOI 10.1007/s11673-010-9208-8.
78. Dyer O. Lilly investigated in US over the marketing of olanzapine. BMJ. 2007; 334: 171.
79. Schneider L. S., Dagerman K. S., Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005; 294: 1934–43.
80. McGauran N., Wieseler B., Kreis J., et al. Reporting bias in medical research – a narrative review. Trials. 2010; 11: 37.
18. Запугивания, угрозы и насилие как метод продаж
Я пришел к осознанию того, что по сравнению с реальностью моя история банальна, как праздничная открытка.
Джон Ле Карре. The Constant Gardener («Преданный садовник»)
Нужно быть очень мужественным человеком, чтобы стать осведомителем. Здравоохранение настолько коррумпировано, что те, кто разоблачают преступные действия фармацевтических компаний, становятся изгоями. Они нарушают прибыльный статус-кво, в котором люди вокруг них процветают на промышленных деньгах: коллеги и начальство, больница, университет, сообщество специалистов, медицинская ассоциация и некоторые политики.
